PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
50.28
+0.90 (1.82%)
Feb 5, 2025, 9:44 AM EST - Market open
PTC Therapeutics Revenue
PTC Therapeutics had revenue of $196.79M in the quarter ending September 30, 2024, with 0.11% growth. This brings the company's revenue in the last twelve months to $900.66M, up 12.84% year-over-year. In the year 2023, PTC Therapeutics had annual revenue of $937.82M with 34.20% growth.
Revenue (ttm)
$900.66M
Revenue Growth
+12.84%
P/S Ratio
4.19
Revenue / Employee
$853,710
Employees
1,055
Market Cap
3.81B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 937.82M | 239.02M | 34.20% |
Dec 31, 2022 | 698.80M | 160.21M | 29.75% |
Dec 31, 2021 | 538.59M | 157.83M | 41.45% |
Dec 31, 2020 | 380.77M | 73.79M | 24.04% |
Dec 31, 2019 | 306.98M | 42.25M | 15.96% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 56.33B |
Novartis AG | 51.72B |
AstraZeneca | 51.21B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
PTCT News
- 22 days ago - PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 23 days ago - PTC Therapeutics Provides Update on Commercial Performance and R&D Pipeline at 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 6 weeks ago - PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 6 weeks ago - PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia - PRNewsWire
- 2 months ago - PTC Therapeutics Stock Soars on Novartis Licensing Agreement - Investopedia
- 2 months ago - PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program - Benzinga
- 2 months ago - PTC Therapeutics signs up to $1.9 billion licensing deal with Novartis - Reuters
- 2 months ago - PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program - PRNewsWire